Abstract

Mps one binder 2 (MOB2) regulates the NDR kinase family, however, whether and how it is implicated in cancer remain unknown. Here we show that MOB2 functions as a tumor suppressor in glioblastoma (GBM). Analysis of MOB2 expression in glioma patient specimens and bioinformatic analyses of public datasets revealed that MOB2 was downregulated at both mRNA and protein levels in GBM. Ectopic MOB2 expression suppressed, while depletion of MOB2 enhanced, the malignant phenotypes of GBM cells, such as clonogenic growth, anoikis resistance, and formation of focal adhesions, migration, and invasion. Moreover, depletion of MOB2 increased, while overexpression of MOB2 decreased, GBM cell metastasis in a chick chorioallantoic membrane model. Overexpression of MOB2-mediated antitumor effects were further confirmed in mouse xenograft models. Mechanistically, MOB2 negatively regulated the FAK/Akt pathway involving integrin. Notably, MOB2 interacted with and promoted PKA signaling in a cAMP-dependent manner. Furthermore, the cAMP activator Forskolin increased, while the PKA inhibitor H89 decreased, MOB2 expression in GBM cells. Functionally, MOB2 contributed to the cAMP/PKA signaling-regulated inactivation of FAK/Akt pathway and inhibition of GBM cell migration and invasion. Collectively, these findings suggest a role of MOB2 as a tumor suppressor in GBM via regulation of FAK/Akt signaling. Additionally, we uncover MOB2 as a novel regulator in cAMP/PKA signaling. Given that small compounds targeting FAK and cAMP pathway have been tested in clinical trials, we suggest that interference with MOB2 expression and function may support a theoretical and therapeutic basis for applications of these compounds.

Details

Title
MOB2 suppresses GBM cell migration and invasion via regulation of FAK/Akt and cAMP/PKA signaling
Author
Jiang, Ke 1 ; Yao, Gang 2 ; Hu, Lulu 2 ; Yan, Yumei 3 ; Liu, Jia 4 ; Shi, Ji 4 ; Chang Youwei 4 ; Zhang, Ye 4 ; Liang Dapeng 2 ; Shen Dachuan 5 ; Zhang, Guirong 6 ; Meng Songshu 2 ; Piao Haozhe 4 

 Liaoning Cancer Hospital & Institute, Department of Neurosurgery, Cancer Hospital of China Medical University, Shenyang, China (GRID:grid.459742.9) (ISNI:0000 0004 1798 5889); Dalian Medical University Cancer Center, Institute of Cancer Stem Cell, Dalian, China (GRID:grid.411971.b) (ISNI:0000 0000 9558 1426) 
 Dalian Medical University Cancer Center, Institute of Cancer Stem Cell, Dalian, China (GRID:grid.411971.b) (ISNI:0000 0000 9558 1426) 
 the First Affiliated Hospital to Dalian Medical University, The First Department of Ultrasound, Dalian, China (GRID:grid.452435.1) 
 Liaoning Cancer Hospital & Institute, Department of Neurosurgery, Cancer Hospital of China Medical University, Shenyang, China (GRID:grid.459742.9) (ISNI:0000 0004 1798 5889) 
 Affiliated Zhongshan Hospital of Dalian University, Department of Oncology, Dalian, China (GRID:grid.459353.d) (ISNI:0000 0004 1800 3285) 
 Liaoning Cancer Hospital & Institute, Central laboratory, Cancer Hospital of China Medical University, Shenyang, China (GRID:grid.459742.9) (ISNI:0000 0004 1798 5889) 
Publication year
2020
Publication date
Apr 2020
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2389682096
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.